Protokinetix, INC 10-Q quarterly reports

ProtoKinetix, a development stage biotech, reported increased losses and a significant accumulated deficit, raising substantial doubt about its ability to continue as a going concern, despite a slight improvement in cash position.

ProtoKinetix, a development stage medical research company, reported an increased net loss and worsening negative working capital in its Q2 2025 filing, highlighting ongoing reliance on equity financing despite a slight cash increase.

ProtoKinetix, a development stage biotechnology company, announced its financial results for the first quarter of 2025, highlighting its continued focus on commercializing its AAGP molecule.

ProtoKinetix, a development-stage biotech company, reported a net loss of $261,676 for the nine months ended September 30, 2024, with a decrease in operating expenses and a focus on securing strategic partnerships for its AAGP molecule.

ProtoKinetix, a development stage company, reported a reduced net loss for the six months ended June 30, 2024, compared to the same period in 2023, while continuing to focus on the commercialization of its AAGP technology.

ProtoKinetix, a development stage company, reported a net loss of $92,026 for the first quarter of 2024, with ongoing efforts to secure additional funding for research and development.